Targeting inhibitory checkpoint molecules has been shown effective in the context of anti-tumor immunity, in which PD-1 is currently the only therapeutic target for CD8+ T cells in NPC clinical trials (20, 51). The gene discussed is CD8A; the disease is nasopharyngeal carcinoma.